Table 4 characteristics of radiotherapy plus surgery group and radiotherapy combined with chemotherapy and surgery group after matching
Characteristics | radiotherapy plus surgery | CTRT plus surgery | ||||
|---|---|---|---|---|---|---|
AC(n = 49) | SCC(n = 49) | P value | AC(n = 305) | SCC(n = 305) | P value | |
age (%) | 0.750 | 0.291 | ||||
< 40 | 9 (18.4) | 9 (18.4) | 84 (27.5) | 78 (25.6) | ||
40–49 | 17 (34.7) | 14 (28.6) | 101 (33.1) | 93 (30.5) | ||
50–59 | 16 (32.7) | 15 (30.6) | 74 (24.3) | 95 (31.1) | ||
60–69 | 7 (14.3) | 11 (22.4) | 46 (15.1) | 39 (12.8) | ||
race (%) | 1.000 | 0.56 | ||||
Black | 3 (6.1) | 3 (6.1) | 17 (5.6) | 16 (5.2) | ||
White | 2 (4.1) | 2 (4.1) | 37 (12.1) | 29 (9.5) | ||
Other | 44 (89.8) | 44 (89.8) | 251 (82.3) | 260 (85.2) | ||
grade (%) | 0.502 | 0.927 | ||||
I | 1 (2.0) | 1 (2.0) | 33 (10.8) | 35 (11.5) | ||
II | 30 (61.2) | 25 (51.0) | 156 (51.1) | 153 (50.2) | ||
III | 17 (34.7) | 23 (46.9) | 109 (35.7) | 112 (36.7) | ||
IV | 1 (2.0) | 0 (0.0) | 7 (2.3) | 5 (1.6) | ||
FIGO stage (%) | 0.378 | 0.066 | ||||
Ib2 | 18 (36.7) | 17 (34.7) | 54 (17.7) | 34 (11.1) | ||
IIa1 | 3 (6.1) | 0 (0.0) | 11 (3.6) | 7 (2.3) | ||
IIa2 | 4 (8.2) | 3 (6.1) | 19 (6.2) | 9 (3.0) | ||
IIb | 5 (10.2) | 12 (24.5) | 57 (18.7) | 60 (19.7) | ||
IIIa | 1 (2.0) | 1 (2.0) | 2 (0.7) | 2 (0.7) | ||
IIIb | 16 (32.7) | 15 (30.6) | 159 (52.1) | 190 (62.3) | ||
IVa | 2 (4.1) | 1 (2.0) | 3 (1.0) | 3 (1.0) | ||
Radiation (%) | 0.659 | 0.988 | ||||
Beam radiation | 34 (69.4) | 34 (69.4) | 145 (47.5) | 144 (47.2) | ||
brachytherapy | 11 (22.4) | 13 (26.5) | 136 (44.6) | 136 (44.6) | ||
BRB | 4 (8.2) | 2 (4.1) | 24 (7.9) | 25 (8.2) | ||
status (%) | 1.000 | |||||
alive | 40 (81.6) | 40 (81.6) | 234 (76.7) | 236 (77.4) | 0.923 | |
dead | 9(18.4) | 9(18.4) | 71(23.3) | 69(22.6) | ||
time (mean (SD)) | 37.9 (22.0) | 39.4(22.1) | 0.749 | 37.3 (20.6) | 37.4(21.0) | 0.939 |